Uri Ladabaum

Jan 6, 2025 | thelancet.com | Uri Ladabaum |Jason A. Dominitz |David Lieberman |Robert Schoen

FREE with registration!Log in or register to access the full article. References1. Chung, DC ∙ Gray, 2nd, DM ∙ Singh, H ∙ et al. A cell-free DNA blood-based test for colorectal cancer screeningN Engl J Med. 2024; 390:973-9832. Morgan, E ∙ Arnold, M ∙ Gini, A ∙ et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCANGut. 2023; 72:338-3443. Lin, JS ∙ Perdue, LA ∙ Henrikson, NB ∙ et al.

Oct 28, 2024 | acpjournals.org | Uri Ladabaum

Screening substantially decreases colorectal cancer (CRC) incidence and mortality through detection of CRC precursors and early-stage CRC (1, 2). The U.S. Preventive Services Task Force (USPSTF) provides a grade A recommendation for CRC screening for ages 50 to 75 years and a grade B recommendation for ages 45 to 49 years (3). Despite the effectiveness of CRC screening, approximately 40% of eligible persons are not up to date with CRC screening in the United States. (4).